v3.25.2
License Agreements - AstraZeneca (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 31, 2019
Jul. 31, 2018
Jun. 30, 2025
Jun. 30, 2024
Sep. 30, 2022
Jun. 30, 2025
Dec. 31, 2024
Jun. 30, 2024
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Amortization of intangible assets           $ 3,542   $ 375
AstraZeneca                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
License agreement, cash payment   $ 1,000            
First milestone cash payment $ 2,000              
Product milestone payment for first product approval         $ 7,500      
Sales milestone payment           10,000 $ 5,000  
Annual net sales           $ 250,000 $ 100,000  
Intangible asset, useful life     10 years     10 years    
Amortization of intangible assets     $ 600 $ 200   $ 3,500   400
Maximum milestone payments for licensed products           5,000    
Royalty expense     $ 2,500 $ 900   $ 4,400   $ 1,600
AstraZeneca | Series B Preferred Stock                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Issuance of convertible preferred stock, net of issuance costs (in shares)   484,388            
Issuance of convertible preferred stock, net of issuance costs   $ 3,000